No adverse event; The patient received her next dose of the bivalent Moderna Covid-19 vaccine on May 19, 2023 / Patient received vaccine past its use by date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (The patient received her next dose of the bivalent Moderna Covid-19 vaccine on May 19, 2023 / Patient received vaccine past its use by date) and NO ADVERSE EVENT (No adverse event) in a 77-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 069H22A) for COVID-19 prophylaxis.     Previously administered products included for COVID-19 prophylaxis: Moderna COVID-19 Vaccine on 16-Feb-2021, Moderna COVID-19 Vaccine on 16-Mar-2021, Moderna COVID-19 Vaccine on 22-Oct-2021, Moderna COVID-19 Vaccine on 18-Apr-2022, MODERNA COVID-19 VACCINE and BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5) on 08-Sep-2022. Past adverse reactions to the above products included No adverse event with MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5), Moderna COVID-19 Vaccine, Moderna COVID-19 Vaccine, Moderna COVID-19 Vaccine and Moderna COVID-19 Vaccine.    On 19-May-2023, the patient received sixth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 19-May-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (The patient received her next dose of the bivalent Moderna Covid-19 vaccine on May 19, 2023 / Patient received vaccine past its use by date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (The patient received her next dose of the bivalent Moderna Covid-19 vaccine on May 19, 2023 / Patient received vaccine past its use by date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (The patient received her next dose of the bivalent Moderna Covid-19 vaccine on May 19, 2023 / Patient received vaccine past its use by date).    There was information about previous COVID-19 vaccination doses. The patient received her first Moderna Covid-19 vaccine on 16 Feb 2021 lot number 015M20A expiration date was not known. Arm of administration was not known. No adverse events were known of.  The patient received her second Moderna primary series vaccine on 16 Mar 2021 lot number 044A21A expiration date was not known. Arm of injection was not known. No adverse events reported.  The patient received a Moderna monovalent booster vaccine on 22 Oct 2021.The patient received in his left arm lot number 939903 expiration date was not known. No adverse reactions were reported.  The patient received a Moderna Covid-19 monovalent booster dose on 18 Apr 2022 lot number 005M21A expiration date July 14, 2022. Patient received vaccine in left arm. No adverse events are known of.  The patient received a Modern Bivalent booster dose on 8 Sept 2022 lot number AS7140C expiration date and arm of administration were not known. No adverse reactions were reported.  The patient received her next dose of the bivalent Moderna Covid-19 vaccine on 19 May 2023, lot number 069H22A expiration date was 18 June 2023 vaccine was administered in her left arm.  Patient received vaccine past it was use by date. Patient received vaccine in her left arm. No other adverse reactions are reported. Concomitant medication not reported. Treatment medication not reported.